TROW Stock Recent News

The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.

The market's recent pullback is over. The S&P has hit record highs, driven by strong earnings growth potential through 2027. Despite the S&P 500's historically high PEGY ratio, robust growth forecasts (10%–15% annual EPS through 2026) mean valuations alone won't necessarily trigger a bear market. These 10‐stock dividend aristocrats are 37% undervalued. They offer an average yield of 3.4% and, if they revert to fair value, the potential to deliver up to 78% upside in 2025.

I've been loading my retirement portfolio with high-quality dividend-paying stocks. While I love the passive income they produce, that's not the primary driver.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

T. Rowe Price (TROW) closed the most recent trading day at $112.84, moving -0.25% from the previous trading session.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

**Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. **Rating Justification:** Six more Aristocrats could meet the ideal dividend-to-price ratio with a 45.4% market downturn, making them fair-priced investment opportunities. **Analyst Projections:** Top-ten Aristocrats are expected to deliver 22% to 33.36% net gains by January 2025, with an average net gain of 24.96%.

In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne Medical, X-Fab Silicon Foundries, and ArcerlorMittal. Analysts' recommendations range from Strong Buy to Strong Sell, covering diverse sectors such as healthcare, technology, energy, and consumer goods.

T. Rowe (TROW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The ProShares S&P 500 Dividend Aristocrat ETF rocked a cool 4.85% gain in November, but it's giving up nearly half of its return this year in December. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 41 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.